Amgen Inc. (NASDAQ:AMGN)’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Romiplostim’s approval was based on the results of a phase-3 trial published in 2008 in The Lancet. The trial included two parallel studies; one enrolled splenectomized patients, and the other ...

The rate of a platelet response in the romiplostim group was 2.3 times that in the standard-of-care group (95% confidence interval [CI], 2.0 to 2.6; P<0.001). Patients receiving romiplostim had a ...

Purpose: The pharmacology, pharmacokinetics, dosage and administration, efficacy, safety, effects on quality of life, and place in therapy of romiplostim are reviewed. Summary: Romiplostim is a ...

Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children’s Oncology Group Study We conducted a phase II randomized trial ...

Newer second-generation thrombopoietin analogs, romiplostim (NPlate, Amgen) and eltrombopag (Promacta/Revolade, GlaxoSmithKline), have been developed. These agents stimulate the thrombopoietin ...

The paper in the Nov. 11 New England Journal of Medicine reports that treatment with romiplostim, which mimics the effects of a growth factor that regulates platelet production, was more than ...

June 12, 2009 (Berlin, Germany) — The platelet-stimulating drug romiplostim (Nplate) prevents a significant number of splenectomies in patients with immune thrombocytopenia (ITP), according to ...

Nplate (romiplostim) is a prescription drug that’s used to increase a low platelet count caused by certain conditions. Nplate comes as a powder that’s mixed with liquid and given as an injecti ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Nplate (Romiplostim) Romiplate - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Nplate ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of romiplostim, having considered evidence on the nature of chronic ITP and the value placed on the benefits ...